NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS, CA
PERMIT # 659

Metabolic Endocrine Education Foundation
18372 Clark Street # 212 Tarzana, CA 91356

Register online: **www.WCIR.org/CMEdinner**
Please choose CME Dinner Symposium from the Menu

CME Dinner Symposium
IN ASSOCIATION WITH THE 17th WCIRDC

EARN
CME
ACCME
CREDIT
2.00

Diabetes and the Cardiorenal Syndrome



Thursday, December 5, 2019
7:30 pm – 9:30 pm

Hilton Universal City Hotel
Los Angeles, CA

This is a CME Symposium Supported by an Educational Grant from **AstraZeneca**

Free for all 17th WCIRDC Attendees | Register Online: wcir.org/registration

Provided By: MEEF FOUNDATION PESI Administered By: TMIOA

Diabetes and the Cardiorenal Syndrome

CHAIR: Peter A. McCullough, MD

7:30 pm – 7:40 pm	Introduction & Pre-CME Questions
7:40 pm – 8:00 pm	The Cardiorenal Syndrome in Diabetes, Epidemiology and Economic Impact **Janani Rangaswami, MD**
8:00 pm – 8:20 pm	Classification, Pathophysiology and Diagnosis of The Cardiorenal Syndrome **Peter A. McCullough, MD**
8:20 pm – 8:40 pm	Contemporary Approach to Management and Prognosis of the Cardiorenal Syndrome in Diabetes **Hector O. Ventura, MD**
8:40 pm – 9:00 pm	Emerging Therapies: The SGLT2 Inhibitors in People with T2D at Risk for Cardiorenal Syndrome **Mark E. Molitch, MD**
9:00 pm – 9:20 pm	**Q&A Panel Discussion:** Practice Implication of CRS- Management and Prevention - Case based **Norman E. Lepor, MD** **Panel:** Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD • Peter A. McCullough, MD Mark E. Molitch, MD, Janani Rangaswami, MD • Hector O. Ventura MD • Matthew R. Weir, MD **Moderator:** Norman E. Lepor, MD
9:20 pm	Post-CME Questions & Concluding Remarks
9:30 pm	Adjourn

Program Description

Chronic kidney disease (CKD) and congestive heart failure (CHF) have major adverse effects on affected individuals and on society. CKD and CHF are closely related, and both share common pathophysiological pathways with type 2 diabetes, including hypertension, inflammation, oxidative stress, and increased renin-angiotensin-aldosterone system activity. Approximately 37% of patients with diabetes and 18% of those with prediabetes have CKD. Medical care for CKD in diabetes accounts for 29% of direct medical costs. Meanwhile, the incidence of CHF is 2.8 times higher in patients with both diabetes and CKD, and over half of heart failure patients have moderate to severe CKD. The relationship between CHF and CKD has been termed the Cardiorenal Syndrome (CRS), which, once developed in individuals, promises a grave outcome. The CRS may be acute or chronic and initiated from the heart or from the kidney. In this symposium will examine the epidemiology, pathophysiology and classification of the CRS. We'll evaluate contemporary approaches to management and emerging concepts, specifically the SGLT2 inhibitors. The symposium will conclude with a case-based panel discussion to identify the best approaches for individual patients.

Learning Objectives

Upon completion of this symposium, participants should be able to:

- Discuss the prevalence, comorbidities, and economic burden of CHF and CKD in patients with diabetes
- Compare and contrast acute and chronic cardiorenal syndrome and describe how heart and kidney defects contribute to disease pathophysiology
- Describe best practices in the management of cardiorenal syndrome in patients with diabetes using medical and procedural interventions
- Discuss the impact of SGLT2 inhibitors on cardiorenal risk in patients with diabetes
- Design optimal therapeutic regimens for the prevention of CKD and CHF in patients with diabetes

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, nephrologists, family physicians, internists, diabetologists, nurse practitioners, physician assistants, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, kidney disease, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

FACULTY 2019

Peter A. McCullough, MD, MPH, FACC FACP, FCCP, FAHA, FNKF, FCRSA Chair
Vice Chief of Medicine
Baylor University Medical Center
Dallas, Texas

Hector O. Ventura, MD, FACC, FACP
Professor of Medicine
Tulane University School Of Medicine Adult Congenital Heart Disease, Heart Failure & Transplantation Section Head Heart Failure And Heart Transplantation Ochsner Clinic President Louisiana Chapter Of The ACC
New Orleans, Louisiana

Janani Rangaswami, MD, FACP, FCRS
Clinical Associate Professor
Sidney Kimmel College of Thomas Jefferson University
Associate Program Director
Department of Medicine/Nephrology
Einstein Medical Center
Philadelphia, Pennsylvania

Yehuda Handelsman, MD FACP, FNLA, MACE
Chair & Program Director, WCIRDC
Medical Director & Principal Investigator, Metabolic Institute of America
Chair & Founder, International Committee for Insulin Resistance
Chair & Founder, International Lipid Forum
Tarzana, California

Norman E. Lepor, MD, FACC, FAHA, FSCAI
Clinical Professor of Medicine
Attending Cardiologist
Cedars-Sinai Heart Institute
Co-director, Cardiovascular Imaging
Westside Medical Imaging
Director of Clinical Research
Westside Medical Associates
Los Angeles, California

Mark E. Molitch, MD
Emeritus Professor of Medicine
Division of Endocrinology, Metabolism & Molecular Medicine
Department of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Mikhail N. Kosiborod, MD, FACC, FAHA
Professor of Medicine
Saint Luke's Mid America Heart Institute
University of Missouri-Kansas City
School of Medicine
Kansas City, Missouri

Matthew R. Weir, MD
Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

CME Dinner Symposium

Free for 17th WCIRDC Attendees | Learn more at www.wcir.org/CMEdinner

Dinner attendance is limited! If you are already registered for the 17th WCIRDC, please email **Jeannine@tmioa.com** to pre-register for this symposium.
To register for the entire 17th WCIRDC, which includes this CME Dinner Symposium, please visit **www.wcir.org/registration**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.

PESI, Inc, designated this live educational activity for a maximum of **2 AMA PRA Category 1 Credit(s)**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact: **info@tmioa.com** or **818.342.1889**

This is a CME Program Supported by an Educational Grant from **AstraZeneca**